147 related articles for article (PubMed ID: 37105495)
1. Identification of Potential Therapeutic Targets for Plasmablastic Lymphoma Through Gene Expression Analysis: Insights into RAS and Wnt Signaling Pathways.
Mansoor A; Kamran H; Akhter A; Seno R; Torlakovic EE; Roshan TM; Shabani-Rad MT; Elyamany G; Minoo P; Stewart D
Mod Pathol; 2023 Aug; 36(8):100198. PubMed ID: 37105495
[TBL] [Abstract][Full Text] [Related]
2. Unraveling the molecular landscape: a comparative analysis of PI3K and MAPK signaling pathways in plasmablastic lymphoma and diffuse large B-cell lymphoma with therapeutic implications.
Mansoor A; Akhter A; Kamran H; Minoo P; Stewart D
Hum Pathol; 2023 Nov; 141():102-109. PubMed ID: 37524252
[TBL] [Abstract][Full Text] [Related]
3. Exploring
Mansoor A; Akhter A; Hamidi M; Roshan TM; Shabani-Rad MT; Stewart D
Anticancer Res; 2023 Nov; 43(11):4801-4807. PubMed ID: 37909960
[TBL] [Abstract][Full Text] [Related]
4. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.
Witte HM; Künstner A; Hertel N; Bernd HW; Bernard V; Stölting S; Merz H; von Bubnoff N; Busch H; Feller AC; Gebauer N
Blood Adv; 2022 Jan; 6(2):637-651. PubMed ID: 34714908
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features and abnormal signaling pathways in plasmablastic lymphoma: a multicenter study in China.
Shi D; Gao L; Wan XC; Li J; Tian T; Hu J; Zhang QL; Su YF; Zeng YP; Hu ZJ; Yu BH; Li XQ; Wei P; Li JW; Zhou XY
BMC Med; 2022 Dec; 20(1):483. PubMed ID: 36522654
[TBL] [Abstract][Full Text] [Related]
6. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.
Ramis-Zaldivar JE; Gonzalez-Farre B; Nicolae A; Pack S; Clot G; Nadeu F; Mottok A; Horn H; Song JY; Fu K; Wright G; Gascoyne RD; Chan WC; Scott DW; Feldman AL; Valera A; Enjuanes A; Braziel RM; Smeland EB; Staudt LM; Rosenwald A; Rimsza LM; Ott G; Jaffe ES; Salaverria I; Campo E
Haematologica; 2021 Oct; 106(10):2682-2693. PubMed ID: 33951889
[TBL] [Abstract][Full Text] [Related]
7. PLAGL2 Promotes the Proliferation and Migration of Diffuse Large B-cell Lymphoma Cells via Wnt/β-catenin Pathway.
Jin W; Wang X
Ann Clin Lab Sci; 2022 May; 52(3):359-366. PubMed ID: 35777795
[TBL] [Abstract][Full Text] [Related]
8. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
9. Exploration and analysis of differentially expressed genes in Epstein-Barr virus negative and positive plasmablastic lymphoma.
Liang Y; Wang H; Luo B
Clin Transl Oncol; 2023 Oct; 25(10):2884-2891. PubMed ID: 36991219
[TBL] [Abstract][Full Text] [Related]
10. LncRNA FIRRE is activated by MYC and promotes the development of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.
Shi X; Cui Z; Liu X; Wu S; Wu Y; Fang F; Zhao H
Biochem Biophys Res Commun; 2019 Mar; 510(4):594-600. PubMed ID: 30739786
[TBL] [Abstract][Full Text] [Related]
11. Hypothesis of Opposite Interplay Between the Canonical WNT/beta-catenin Pathway and PPAR Gamma in Primary Central Nervous System Lymphomas.
Vallée A; Lecarpentier Y; Vallée JN
Curr Issues Mol Biol; 2019; 31():1-20. PubMed ID: 30647194
[TBL] [Abstract][Full Text] [Related]
12. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.
Zhao CX; Yan ZX; Wen JJ; Fu D; Xu PP; Wang L; Cheng S; Hu JD; Zhao WL
Mol Cancer; 2021 Dec; 20(1):153. PubMed ID: 34852843
[TBL] [Abstract][Full Text] [Related]
13. Diffuse large B-cell lymphomas with plasmablastic differentiation.
Teruya-Feldstein J
Curr Oncol Rep; 2005 Sep; 7(5):357-63. PubMed ID: 16091196
[TBL] [Abstract][Full Text] [Related]
14. FOXM1-induced upregulation of lncRNA OR3A4 promotes the progression of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.
Meng H; Zhao B; Wang Y
Exp Mol Pathol; 2020 Aug; 115():104451. PubMed ID: 32417392
[TBL] [Abstract][Full Text] [Related]
15. Plasmablastic Lymphoma Presenting as Extensive Peritoneal and Retroperitoneal Nodules in an HIV-Positive Patient.
Pokhrel A; Yuldasheva O; Mirashi E; Nair K; Salyana M; Jaswani V; Avezbakiyev B; Wang JC
J Investig Med High Impact Case Rep; 2022; 10():23247096211065633. PubMed ID: 35073776
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
[TBL] [Abstract][Full Text] [Related]
17. GPNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt/β-catenin signaling pathway.
Wang Z; Ran X; Qian S; Hou H; Dong M; Wu S; Ding M; Zhang Y; Zhang X; Zhang M; Chen Q
Arch Biochem Biophys; 2021 Oct; 710():108998. PubMed ID: 34280359
[TBL] [Abstract][Full Text] [Related]
18. Clonally Related Plasmablastic Lymphoma Simultaneously Occurring with Diffuse Large B-Cell Lymphoma.
Hashimoto N; Ueda T; Hiraiwa S; Tajiri T; Nakamura N; Yokoyama K
Case Rep Hematol; 2020; 2020():8876567. PubMed ID: 33335784
[TBL] [Abstract][Full Text] [Related]
19. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
Xia Y; Xu-Monette ZY; Tzankov A; Li X; Manyam GC; Murty V; Bhagat G; Zhang S; Pasqualucci L; Visco C; Dybkaer K; Chiu A; Orazi A; Zu Y; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Westin J; Fowler N; Miranda RN; Ok CY; Li Y; Li J; Medeiros LJ; Young KH
Leukemia; 2017 Mar; 31(3):625-636. PubMed ID: 27568520
[TBL] [Abstract][Full Text] [Related]
20. Plasmablastic lymphoma of the retroperitoneum in an HIV- and HCV-positive patient: hard to diagnose and harder to treat.
Dholaria B; Alapat D; Pandey T; Agarwal A
Med Oncol; 2012 Dec; 29(5):3529-34. PubMed ID: 22562157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
